GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$50.36
0.69 (1.39%)
▲
5d:
+1.1%
30d:
-13.69%
90d:
-17.27%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GSK shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GSK shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$75.26
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$46.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $50.36, which is considered oversold relative to its 30-day fair value range of $50.49 to $57.11. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.5) compared to its historical average (10.7). Remarkably, the market is currently pricing in an annual earnings decline of 4.1% over the next few years. This pessimistic expectation contrasts with the company's recent 8.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $49.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $57.66 (+16.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $49.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $57.66 (+16.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$50.49 -
$57.11
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
54.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($57.66)
Trading Range Analysis
30-Day Trading Range
$50.49 -
$57.11
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$49.39
Resistance Level
$51.31
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.49
Wall Street Target
$57.67
(+16.1%)
Revenue Growth (YoY)
1.5%
Earnings Growth (YoY)
8.4%
Profit Margin
17.8%
Valuation Discount vs History
-4.1% cheaper
PE vs Historical
9.5 vs 10.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.1%
(market-implied from PE analysis)
1-Year Target
$47.63
(-4%)
2-Year Target
$45.68
(-8%)
3-Year Target
$43.81
(-12%)
3-Yr Target (if PE normalizes)
(PE: 9→11)
$49.39
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 8.2%)
$146.18
(+194%)
Base:
(SPY PE: 9.5, Growth: 8.2%)
$62.86
(+27%)
Bear:
(PE: 8.1, Growth: 8.2%)
$53.43
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.90 | Current EPS (TTM): $3.85
Bull Case
$74.26
(+50%)
Analyst growth 35.9%, PE expands to 14.2
Base Case
$67.51
(+36%)
Market implied 35.9%, PE stable at 12.9
Bear Case
$33.77
(-32%)
Severe decline -20.0%, PE contracts to 11.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.5 to 10.7
Stabilization Target:
$56.00
(+12.7%)
PE Expansion Potential:
+12.7%
Share & Embed Analysis
Last updated: May 18, 2026 12:20 PM ET
Data refreshes hourly during market hours. Next update: 1:20 PM
Data refreshes hourly during market hours. Next update: 1:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Plc Gsk
BUY
1470000 shares
2025-12-11
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1210 | 62 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$253 | 65 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$218 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 60 HOLD |
